Related references
Note: Only part of the references are listed.Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
Florian Moik et al.
BLOOD (2021)
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti et al.
CANCERS (2020)
An overview of thrombotic complications of old and new anticancer drugs
Marcel Levi et al.
THROMBOSIS RESEARCH (2020)
The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC
Wei Xiong et al.
RESPIRATORY RESEARCH (2020)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon et al.
LANCET ONCOLOGY (2018)
Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Kyaw Zin Thein et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer
H. E. Fuentes et al.
THROMBOSIS RESEARCH (2017)
Venous Thromboembolism in Patients Diagnosed With Lung Cancer
E. Salla et al.
ANGIOLOGY (2016)
Cross Talk Pathways Between Coagulation and Inflammation
Jonathan H. Foley et al.
CIRCULATION RESEARCH (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Venous thromboembolism and lung cancer: a review
Carolina Vitale et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2015)
Prevalence and Associations of VTE in Patients With Newly Diagnosed Lung Cancer
Yuhui Zhang et al.
CHEST (2014)
30-Year Mortality After Venous Thromboembolism A Population-Based Cohort Study
Kirstine Kobberoe Sogaard et al.
CIRCULATION (2014)
Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice
Clement Cochain et al.
PLOS ONE (2014)
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
F. Petrelli et al.
ANNALS OF ONCOLOGY (2012)
A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer
Rafael D. Malgor et al.
ANNALS OF THORACIC SURGERY (2012)
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
Sonia Seng et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lung cancer associated venous thromboembolic disease: A comprehensive review
Luis Corrales-Rodriguez et al.
LUNG CANCER (2012)
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
G. C. Connolly et al.
LUNG CANCER (2012)
Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
De-xiu Bu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
Russell A. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prediction of venous thromboembolism in cancer patients
Cihan Ay et al.
BLOOD (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
Lucio Crino et al.
LANCET ONCOLOGY (2010)
Venous thromboembolism and prognosis in cancer
Alok A. Khorana
THROMBOSIS RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism -: Findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry
Silvy Laporte et al.
CIRCULATION (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High risk of deep vein thrombosis in patients with non-small cell lung cancer: A cohort study of 493 patients
Vicky Tagalakis et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Risk factors for venous thromboembolic events in cancer patients
K Kröger et al.
ANNALS OF ONCOLOGY (2006)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma
JW Blom et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Prognosis of cancers associated with venous thromboembolism.
HT Sorensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
